Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial - PubMed
2 hours ago
- #glomerular disease
- #finerenone
- #chronic kidney disease
- Finerenone is a nonsteroidal mineralocorticoid receptor antagonist evaluated for patients with CKD due to glomerular diseases.
- This exploratory analysis from a phase 3 trial involved 903 participants with glomerular diseases, including IgA nephropathy, FSGS, and membranous nephropathy.
- Finerenone slowed the annual eGFR decline (−3.50 vs. −4.23 mL/min/1.73 m²/year with placebo) over 32 months.
- The treatment reduced albuminuria by 42% at 12 months and lowered the risk of kidney failure or ≥40% eGFR decline (HR 0.74).
- Finerenone showed efficacy and safety in preserving kidney function in this population.